OBJECTIVES: To evaluate efficacy and safety of the anti-IL-17 drug secukinumab in a real-life large cohort of patients with moderate-to-severe plaque psoriasis in Central Italy. METHODS: Multicenter, retrospective study with an observation period of up to 52 weeks. Efficacy was assessed by Psoriasis Area and Severity Index (PASI) score; clinical and laboratory examinations were performed at baseline and at weeks 4, 12, 24, 36, and 52. RESULTS: A 90% and a 100% PASI score reduction (PASI90 and PASI100) were reported in 67.5% and 55% of patients at week 12, respectively. A rapid improvement of skin lesions was observed particularly in young patients and in patients naïve to biologics: at week 4, the achievement of PASI90 and PASI100 was higher in younger patients (odds ratio [OR] 0.95, and 0.95; p = 0.003, and 0.005, respectively); PASI90 was achieved by 42.0% of patients naïve to biologics and by 17.0% of patients with prior exposure to biologics (PBT) (OR 0.24; p = 0.001); and PASI100 was reached by 25.5% of naïve patients and 9.8% of PBT (OR 0.28; p = 0.015).The drug was well tolerated. CONCLUSION: Secukinumab was effective in this real-life analysis, with rapid clinical improvement and long-term maintenance of results.
OBJECTIVES: To evaluate efficacy and safety of the anti-IL-17 drug secukinumab in a real-life large cohort of patients with moderate-to-severe plaque psoriasis in Central Italy. METHODS: Multicenter, retrospective study with an observation period of up to 52 weeks. Efficacy was assessed by Psoriasis Area and Severity Index (PASI) score; clinical and laboratory examinations were performed at baseline and at weeks 4, 12, 24, 36, and 52. RESULTS: A 90% and a 100% PASI score reduction (PASI90 and PASI100) were reported in 67.5% and 55% of patients at week 12, respectively. A rapid improvement of skin lesions was observed particularly in young patients and in patients naïve to biologics: at week 4, the achievement of PASI90 and PASI100 was higher in younger patients (odds ratio [OR] 0.95, and 0.95; p = 0.003, and 0.005, respectively); PASI90 was achieved by 42.0% of patients naïve to biologics and by 17.0% of patients with prior exposure to biologics (PBT) (OR 0.24; p = 0.001); and PASI100 was reached by 25.5% of naïve patients and 9.8% of PBT (OR 0.28; p = 0.015).The drug was well tolerated. CONCLUSION: Secukinumab was effective in this real-life analysis, with rapid clinical improvement and long-term maintenance of results.
Entities:
Keywords:
Anti-IL-17; PASI100; biologic drugs; psoriasis; real life; secukinumab
Authors: Antonio Costanzo; Filomena Russo; Marco Galluzzo; Luca Stingeni; Roberta Scuderi; Leonardo Zichichi; Manuela Papini; Luisa Di Costanzo; Andrea Conti; Martina Burlando; Andrea Chiricozzi; Francesca Maria Gaiani; Cristina Mugheddu; Maria Letizia Musumeci; Paolo Gisondi; Stefano Piaserico; Paolo Dapavo; Marina Venturini; Gianluca Pagnanelli; Paolo Amerio; Concetta Potenza; Ketty Peris; Franca Cantoresi; Sara Trevisini; Francesco Loconsole; Annamaria Offidani; Santo Raffaele Mercuri; Viviana Lora; Francesca Prignano; Marta Bartezaghi; Giovanni Oliva; Elisabetta Aloisi; Roberto Orsenigo Journal: Acta Derm Venereol Date: 2021-10-21 Impact factor: 3.875
Authors: J Seneschal; J-P Lacour; A Bewley; M Faurby; C Paul; G Pellacani; C De Simone; L Horne; A Sohrt; M Augustin; E Hammond; K Reich Journal: J Eur Acad Dermatol Venereol Date: 2020-06-08 Impact factor: 6.166